Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials
- 1 August 2006
- journal article
- Published by Elsevier BV in The Lancet
- Vol. 368 (9534), 466-475
- https://doi.org/10.1016/s0140-6736(06)69154-x
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) TrialsClinical Infectious Diseases, 2006
- Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavirAntiviral Research, 2005
- Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy VolunteersHIV Research & Clinical Practice, 2004
- Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study GroupThe Journal of Infectious Diseases, 2004
- Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classesThe Lancet, 2004
- A 14-Day Dose-Response Study of the Efficacy, Safety, and Pharmacokinetics of the Nonpeptidic Protease Inhibitor Tipranavir in Treatment-Naive HIV-1???Infected PatientsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Determinants of Virological Response to Antiretroviral Therapy: Implications for Long-Term StrategiesClinical Infectious Diseases, 2000
- In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitorsAIDS, 2000
- Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide ClassJournal of Medicinal Chemistry, 1998
- Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitorAntimicrobial Agents and Chemotherapy, 1997